Present Possibilities of Therapy in Relapsing Papillomatosis of Larynx

Česká verzia

Authors: H. Kopřivová; Karol Zeleník ; Pavel Komínek
Authors place of work: ORL klinika Fakultní Nemocnice Ostrava přednosta doc. MUDr. P. Komínek, Ph. D., MBA
Published in the journal: Otorinolaryngol Foniatr, 59, 2010, No. 4, pp. 235-240.
Category: Review Article

Summary

Recurrent respiratory papillomatosis (RRP) is caused by the human papillomavirus (HPV) types 6 and 11. It affects both children and adults. The disease is potentially very aggressive and tends to recur and spread into the respiratory tract. Younger age at diagnosis is associated with more serious course of the disease. The standard of care is surgical removal, but in patients with aggressive disease, adjuvant therapy is indicated. Contemporary opinions on cidofovir, interferon, anti-reflux medication etc. are presented. Recently, a preventative quadrivalent vaccine against HPV types 6, 11, 16, 18 has become available. In future generations it may decrease the incidence of RRP. Possible favourable change of the disease course after vaccination is being evaluated presently.

Key words:
recurrent respiratory papillomatosis, human papilloma virus, cidofovir, HPV vaccination

Zdroje

1. Broekema, F. I., Dikkers, F. G.: Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch. Otorhinolaryngol, 265, 2008, s. 871-879.

2. Derkay, C. S., Wiatrak, B.: Recurrent respiratory papillomatosis: a review. Laryngoscope, 118, 2008, s. 1236-1247.

3. Forster, G., Boltze, C., Seidel, J. et al.: Juvenilie Larynxpapillomatose – Impfung mit dem polyvalenten Spaltimpfstoff Gardasil. Laryngo-Rhino-Otol, 87, 2008, s. 796-799.

4. Freed, G. L., Derkay, C. S.: Prevention of recurrent respiratory papillomatosis: Role of HPV vaccination. International Joural od Pediatric Otorhinolaryngology, 70, 2006, s. 1799-1803.

5. Gallagher, T. Q., Derkay C. S.: Pharmacotherapy of recurrent respiratory papillomatosis: an expert opinion. Expert Opin Pharmacoter, 10, 2009, 4, s. 645-655.

6. Gallagher, T. Q., Derkay C. S.: Recurrent respiratory papillomatosis: update 2008. Curr Opin Otolaryngol Head Neck Surg., 16, 2008, s. 536-542.

7. Gerein, V., Rastorguev, E., Gerein, J. et al.: Use of interferon-alpha in recurrent respiratory papillomatosis: 20–year follow up. Ann. Otol Rhinol Laryngol, 114, 2005, s. 463-471

8. Goldemund, K., Máchalová, M., Šlapák, I. et al.: Recidivující papilomatóza laryngu a změna průběhu onemocnění při vakcinaci proti humánnímu papillomaviru, Pediatr. pro praxi, 11, 2010, s. 115-117.

9. Goon, P., Sonnex, Ch., Jani, P., Stanley, M.: Recurent respiratory papillomatosis: an overview of current thinking nd treatment. Eur Arch. Otolaryngol, 265, 2008, s. 147-151.

10. Chhetri, D. K., Shapiro, N. L.: A Schedule protocol for the treatment of juvenile reccurent respiratory papillomatosis with intralesional cidofovir. Arch. Otolryngol Head Neck Surg., 2003, s. 1081-1085.

11. Kashima, H., Shah, F., Lyles, A. et al.: A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope, 102, 1992, s. 9-13.

12. Klozar, J., Klimák, P., Kodet, R. et al.: HPV a riziko orálního a orofaryngeálního karcinomu. Otorinolaryng. a Foniat./Prague/, 2004, č. 2., s. 60 64.

13. Klozar, J., Zábrodský, M., Kodet, R. et al: Humánní papillomaviry v etiologii karcinomu ústní dutiny a orofaryngu. Otorinolaryng. a Foniat. /Prague/, 2007, č. 2., s. 73-81.

14. Leung, R., Hawkes, M., Campisi, P.: Severity of juvenilie onset recurrent respiratory papillomatosis is not asociated with socioeconomic status in setting of universal healthcare. Int. J. Pediatr. Otorhinolaryngol, 71, 2007, s. 965-972.

15. Maloney, E. M., Unger, E. R., Tucker, R. A. et al.: Longitudinal measures of human papilomavirus 6 and 11 viral loads and antibody response in children with recurrent respiratory papillomatosis. Arch. Otolaryngol Head Neck Surg., 132, 2006, s. 711-715.

16. Mammas I. N., Sourvinos, G., Spandidos, D. A.: Human papilloma virus infection in children and adolescent. Eur J. Pediatr., 168, 2009, s. 267-273.

17. McKenna, M., Brodsky, L.: Extraesophageal acid refux and recurrent respiratory papillomatosis is children. International Joural od Pediatric Otorhinolaryngology, 69, 2005, s. 597-605.

18. Pawlita, M., Gissmann, L.: Rekurrierende respiratorische papillomatose. Indikation fur HPV – Vakzination? Dtsch Me Wochenschr, 134, 2009, s. 100-102.

19. Peterka, T.: Očkování proti karcinomu hrdla děložního a dalším projevům HPV infekce. Praktický lékař, 89, 2009, s. 8-10.

20. Pransky, S. M., Margit, A. E., Kearns D. B. et al.: Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch. Otolaryngol Head Neck Surg., 125, 1999, s. 1143-1148.

21. Rotnáglová, E., Tachezy, R., Saláková, M. et al.: Vztah lidských papillomavirů a etiologie karcinomů patrových mandlí. Otorinolaryng. a Foniat. /Prague/, 2010, č. 1, s. 32-37.

22. Schaffer, A., Brotherton, J., Booy, R.: Do human papillomavirus vaccines have any role in newborns and the prevention of reccurent respiratory papillomatosis in children? Journal of Paediatrics and Child Health, 2007, 43, s. 579-580.

23. Stern, Y., Felipovich, A., Cotton, R. et al.: Immunocompetency in children with recurrent respiratory papillomatosis: prospective study. Ann Otol Rhinol Laryngál, 116, 2007, s. 169-171.

24. Tachezy, R., Hamšíková, E., Valvoda, J. et al.: Antibody response to a synthetic peptide derived from the human papillomavirus type 6/11 L2 protein in recurrent respiratory papillomatosis: correlation between Southern blot hybridization, polymerase chain reaction and serology, Journal of Medicinal Virology, 42, 1994, s. 52-59.

25. Tanna, N., Sidell, D., Joshi, A. S. et al.: Adult intralesional cidofovir therapy for laryngeal papilloma. Arch. Otolaryngol Head Neck Surg., 134, 2008, s. 497-500.

26. Villa, L. L., Ault, K. A., Giuliano, A. R. et al.: Imunologic response following administration of vaccine targeting human papillomavirus types 6,11,16 and 18, Vaccine, 2006, 24, s. 5571-5583.

27. Villa, L. L., Costa, R. L. R., Petta, C. A. et al.: High sustained efficiacy of prophylactis quadrivalent human papillomavirus types 6/11/16/18 L1 virus – like particle vaccine through 5 years of follow-up, British Journal of Cancer, 95, 2006, s. 1459-1466.

28. Villa, L. L., Costa, R. L. R., Petta, C. A. et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus like particle vaccine in young women: a randomised double blind placebo – controlled multicentre phase II efficiacy trial, Lancet Oncol., 2005, 6, s. 271-278.